Date: 2015-11-03
Type of information: Series A financing round
Company: ElsaLys Biotech (France)
Investors: Sofimac Partners (France) IM Europe (France) Crédit Agricole Création (France)
Amount: € 2.7 million
Funding type: series A financing round
Planned used: ElsaLys Biotech has been founded in 2013 with the support of Transgene and Sofimac Partners. The company is led by Dr Christine Guillen and consists of a team of nine people. Elsalys Biotech designs and develops innovative therapeutic antibodies in oncology and ophthalmology. These \"best-in-disease\" antibodies aim for innovative targets involved in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. To drive these innovations, ElsaLys Biotech relies on an academic network of international standing, an R&D platform that covers validation of targets in the clinical evaluation of antibody candidates and a team of experts dedicated to developing immune-based therapies. The company has already signed licensing option and / or collaboration agreements (Institut Curie, IGBMC-ICS, Inserm, Centre Léon Bérard, CNRS) and maturation agreements (SATT Conectus, SATT SE), and has acquired a first strategic asset, an anti-CD160 antibody. Two years after its foundation, the Company hosts three proprietary antibodies and four development programmes. This new funding allows ElsaLys Biotech to support the development of its antibodies, including its anti-CD160 developed for ophthalmology and oncology indications. With the completion of a toxicology study, the anti-CD160 programme for ophthalmology would thus reach an important milestone in its preclinical evaluation. This funding will also allow its two other antibodies developed for oncology - anti-CD160 and anti-TYRO3 - to reach preclinical proof of concept.
Others: * On November 3, 2015, ElsaLys Biotech, a biopharmaceutical company dedicated to the development of \"best-in-disease\" therapeutic antibodies for oncology and ophthalmology, announced that it has completed the first instalment of a € 5 million fundraising. This first instalment of € 2.7 million was subscribed by Sofimac Partners, already a shareholder, and by IM Europe, a subsidiary of Institut Mérieux and Crédit Agricole Création.
Therapeutic area: Cancer - Oncology - Ophtalmological diseases
